Francesca Mateo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Francesca Mateo has a total of 628 co-authors. Here are the top co-authors by number of shared publications:
- Miquel Angel Pujana
ProCURE, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
47 shared publications - Holger Heyn
Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain
37 shared publications - Violeta Serra
Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
36 shared publications - Alba Llop-Guevara
Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
35 shared publications - Alba Mas Malavila
Bioinformatics Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
35 shared publications - Andrea Herencia-Ropero
Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
35 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
Cabergoline Suppresses Postpartum Breast Cancer by Enhancing Mammary Gland Involution in Brca1-Mutant Mice and Is Associated with Reduced Risk in Younger Women
Breast cancer that arises in the postpartum period often carries a poor prognosis and urgently requires chemoprevention strategies, particularly for women at elevated risk. Here, we report that a single post-lactation dose of cabergoline, a dopaminergic agonist that blocks prolactin secretion, delays the onset and reduces the incidence of postpartum mammary cancer in K14-Cre; Brca1F/F, Trp53F/F mice. In these mice, cabergoline treatment remodels the mammary gland by potentiating involution, reducing ductal area and proliferation, and reversing T cell exhaustion, potentially through modulation of ion channel expression. Notably, independent retrospective studies in two large cohorts of European women showed that cabergoline treatment was associated with a lower incidence of postpartum breast cancer, with a meta-analysis indicating an approximate 69% reduction in risk. Our work underscores the importance of targeting postlactational involution as a strategy for the prevention of postpartum breast cancer and positions cabergoline as a novel, low-risk chemoprevention strategy.
- 15 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
Open AccessCabergoline Suppresses Postpartum Breast Cancer by Enhancing Mammary Gland Involution in Brca1-Mutant Mice and Is Associated with Reduced Risk in Younger Women
Breast cancer that arises in the postpartum period often carries a poor prognosis and urgently requires chemoprevention strategies, particularly for women at elevated risk. Here, we report that a single post-lactation dose of cabergoline, a dopaminergic agonist that blocks prolactin secretion, delays the onset and reduces the incidence of postpartum mammary cancer in K14-Cre; Brca1F/F, Trp53F/F mice. In these mice, cabergoline treatment remodels the mammary gland by potentiating involution, reducing ductal area and proliferation, and reversing T cell exhaustion, potentially through modulation of ion channel expression. Notably, independent retrospective studies in two large cohorts of European women showed that cabergoline treatment was associated with a lower incidence of postpartum breast cancer, with a meta-analysis indicating an approximate 69% reduction in risk. Our work underscores the importance of targeting postlactational involution as a strategy for the prevention of postpartum breast cancer and positions cabergoline as a novel, low-risk chemoprevention strategy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
MDA single cells annotation in cell types
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
MDA single cells annotation in cell types
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Natural Killer (NK) cells depletion in vivo
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Natural Killer (NK) cells depletion in vivo
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Coupled single cell RNA and TCR sequencing reveals hyperexpanded TCR clonotypes expressing tumor related signatures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Coupled single cell RNA and TCR sequencing reveals hyperexpanded TCR clonotypes expressing tumor related signatures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
PARPi affects the peripheral immune composition in patients
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
PARPi affects the peripheral immune composition in patients
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Interferon responses up-regulation in MDA tumor microenvironment
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Interferon responses up-regulation in MDA tumor microenvironment
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
STING-related biomarkers in BC PDXs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
STING-related biomarkers in BC PDXs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Bulk RNA sequencing of PDX230OR8 tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Bulk RNA sequencing of PDX230OR8 tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Same HRR functionality, PARP enzymatic inhibition and DNA damage in different mouse strains
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Same HRR functionality, PARP enzymatic inhibition and DNA damage in different mouse strains